<DOC>
	<DOCNO>NCT00250653</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety saredutant ( SR48968C ) adult elderly patient depression.The primary objective evaluate long-term safety tolerability 100 mg dose saredutant adult elderly patient depression . The secondary objective evaluate blood level saredutant .</brief_summary>
	<brief_title>A Fifty-two-week Study Evaluate Safety Saredutant Adult Elderly Patients With Depression</brief_title>
	<detailed_description>The study multicenter , US , open-label study consist two segment ( A B ) . Segment A minimum 1-week ( maximum 4-week ) screen period Segment B 52-week , open-label period . All treated patient must complete post-study telephone visit post-study office visit 3 day 1 week , respectively , intake last dose study medication .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<criteria>Male female patient . At least 18 year age . Inpatients outpatient . Written informed consent patient and/or legally authorize representative . Able comply protocol follow write verbal instruction . Subjects childbearing potential must confirm negative serum bhCG test prior entry Segment B must employ acceptable method birth control ( e.g. , oral , depot , implant contraceptive method , IUDs , sterilization , barrier method conjunction spermicide ) . Diagnosis major depressive disorder , define Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision criterion confirm semistructured Mini International Neuropsychiatric Interview ( MINI ) , recurrent episode least one month prior entry . Minimum total score 18 Hamilton Depression Rating Scale ( HAMD ) . Patients whose current depressive episode diagnose psychotic feature , catatonic feature , seasonal pattern postpartum onset . The duration current depressive episode great 2 year . Patients currently suicidal history suicide attempt within 3 year prior entry . Patients whose current depressive episode secondary general medical disorder . Patients history presence bipolar disorder psychotic disorder accord D L criterion MINI . Patients alcohol dependence abuse substance dependence abuse past 12 month except nicotine caffeine dependence . Patients history failure respond treatment paroxetine antidepressant medication . Patients use follow prior entry Segment B : fluoxetine within 28 day , monoamine oxidase inhibitor within 21 day , antidepressant , anxiolytic , sedativehypnotic , moodstabilizer ( lithium , anticonvulsant ) within 7 day except permitted concomitant medication . Females pregnant breastfeeding . Severe unstable cardiovascular , renal , hepatic , respiratory , hematological , endocrinological , neurological , somatic disease might interfere evaluation study medication . History seizure single childhood febrile seizure . ECG abnormalities potential clinical significance include QT interval Bazett 's correction 500 msec entry . Use known inducer potent inhibitor CYP3A4 within 7 day entry . Use drug know risk Torsade de Pointes within 7 day entry Segment B . Participation clinical trial experimental therapy within 30 day prior entry prior participation clinical trial saredutant . Patients positive HbsAg antiHCV antibody test screening . Patients follow screening : ALT &gt; 2 time upper limit normal range ( XULN ) , AST &gt; 2XULN , GGT &gt; 3XULN , total conjugate bilirubin &gt; ULN Elderly patient MiniMental State Examination total score &lt; 25 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>depression</keyword>
	<keyword>antidepressive agent</keyword>
	<keyword>clinical trial</keyword>
</DOC>